Alcon Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALC research report →
Range $35 – $98
Price Chart
About the company
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care.
- CEO
- David J. Endicott
- IPO
- 2019
- Employees
- 25,000
- HQ
- Geneva, GE, CH
Get TickerSpark's AI analysis on ALC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $35.70B
- P/E
- 55.34
- Fwd P/E
- 21.66
- PEG
- -1.54
- P/S
- 3.31
- P/B
- 1.67
- EV/EBITDA
- 14.31
- Div Yield
- 0.48%
- Gross Margin
- 57.32%
- Op Margin
- 10.21%
- Net Margin
- 6.06%
- ROE
- 3.02%
- ROIC
- 3.29%
Latest fiscal year · YoY change
- Revenue
- $10.40B+4.9%
- Gross Profit
- $5.75B+4.2%
- Op Income
- $1.36B
- Net Income
- $980.00M-3.7%
- EPS
- $1.99-3.4%
- OCF Growth
- +9.3%
- FCF Growth
- +14.3%
- 52W High
- $87.64
- 52W Low
- $61.84
- 50D MA
- $68.44
- 200D MA
- $71.54
- Beta
- 0.72
- RSI (14)
- 59
- Avg Volume
- 1.97M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Alcon delivered 5% third-quarter sales growth and raised confidence in full-year execution, while emphasizing new product launches, premiumization, and Neurotech as key growth drivers.· November 11, 2026
- Q3 sales were $2.7 billion, up 5% year over year; core EPS was $0.91, up 15%.
- Core gross margin was 65.7%, up 280 basis points, helped by tariff refunds and manufacturing efficiencies.
- Management kept 2026 sales growth at approximately 6% and narrowed core EPS growth to 12% to 14% and core operating margin expansion to 100 to 150 basis points.
- Surgical grew 4% to $1.5 billion, led by equipment up 11% and consumables up 6%, while implantables fell 2% on U.S. competition.
- Vision Care grew 6% to $1.2 billion, with contact lenses up 5% and ocular health up 8%; TRYPTYR, SYSTANE and contact-lens premiumization were highlighted.
Third-quarter sales were $2.7 billion, up 5% versus prior year, and year-to-date sales were up 6%. Core diluted EPS was $0.91, up 15% year over year. Core gross margin was 65.7%, up 280 basis points year over year; core operating income was $591 million, or 21.8% of sales, up 150 basis points; and the core effective tax rate was 17.8%. Surgical sales grew 4% to $1.5 billion, with implantables at $422 million, down 2%, consumables at $789 million, up 6%, and equipment at $269 million, up 11%. Vision Care sales were $1.2 billion, up 6%, with contact lens sales up 5% to $737 million and ocular health sales up 8% to $500 million. For 2026, management now expects approximately 6% sales growth, core operating margin expansion of 100 to 150 basis points, and core diluted EPS growth of 12% to 14%.
David Endicott said the quarter showed solid momentum across the portfolio, with innovation and premiumization supporting growth despite competitive pressure in U.S. implantables and a softer market backdrop. He stressed that Alcon is getting better traction from a steady cadence of launches, citing PanOptix PRO, Vivity PRO, TruePlus, TRYPTYR, Brightly, Valeda, and Neurotech as examples of building long-term differentiation. His tone was confident and constructive, but he repeatedly acknowledged that the company is operating in a market that is growing at the low end of its assumptions.
Timothy Stonesipher said Q3 sales of $2.7 billion were up 5%, core gross margin reached 65.7%, and core EPS was $0.91, all tracking to the midpoint of the original 2026 plan. He said the gross margin expansion was largely driven by tariff refunds and manufacturing efficiencies, while operating income benefited from the same factors and was partially offset by higher sales and marketing spend. He also noted more than $1.3 billion of free cash flow in the first nine months, $748 million returned to shareholders through dividends and buybacks, and over one-third of the $1.5 billion repurchase authorization completed; for 2027, he flagged a gross 150 to 200 basis points of leverage potential before headwinds, including $60 million of tariff refunds and a $15 million milestone payment that will not recur, plus inflation and Neurotech-related pressure.
Analysts focused on 2027 growth and margin mechanics, Unity/VCS and CS install pace, Brightly launch inventory, implantables competition, and the Neurotech opportunity. Management said Unity unit placements next year should be similar to this year, with a mix shift toward the larger CS market supporting higher total dollars even if ASPs are lower. On implantables, they said the U.S. saw extraordinary competitive activity and that Vivity PRO, TruePlus, and PanOptix PRO should help return the business to growth next year; on Neurotech, they emphasized that the key variable is how quickly diagnosed patients can be found, referred, reimbursed, and treated, and declined to give 2026 sales or a formal 2027 guide.
The bull case from this call is that Alcon is still growing faster than its underlying markets through product launches and mix improvement. Management pointed to strength in equipment, contact lenses, ocular health, and a pipeline that now includes Vivity PRO, Brightly, TRYPTYR, Valeda, and Neurotech, all of which could add to growth in 2027 and beyond.
The main risks discussed were competitive pressure in U.S. premium IOLs, slower implantables growth, and a market environment that is only growing around 3%, below original assumptions. Management also highlighted nonrecurring tariff refunds, inflation, and Neurotech integration pressure as reasons 2027 margin expansion will be harder to model, while emphasizing that reimbursement, patient identification, and surgical adoption will determine how quickly Neurotech can scale.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.7%
- Shares Outstanding
- 480.40M
- Float Shares
- 478.87M
of shares held by institutions
673 13F filers
Congressional trading
Senate and House stock disclosures for ALC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Kevin HernHouse · OK01 | Sell | Aug 5, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 30, 26 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Mar 12, 26 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Mar 3, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 21, 24 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jul 10, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Feb 17, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 11, 22 | Filing → |
| Peter MeijerHouse · MI03 | Sell | Feb 17, 21 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Oct 16, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jun 2, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jun 3, 20 | Filing → |
| Greg GianforteHouse · MT00 | Buy | Jun 5, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 21.46M | ▲ 269.34K |
| Vanguard Capital Management LLC | 14.75M | ▼ 122.03K |
| Invesco Ltd. | 11.46M | ▲ 1.08M |
| Norges Bank | 10.98M | ▲ 10.98M |
| Bank Of New York Mellon Corp | 10.14M | ▼ 2.92M |
| Ako Capital Llp | 9.68M | ▲ 358.35K |
| Aristotle Capital Management, LLC | 9.15M | ▼ 565.77K |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 8.01M | ▲ 97.63K |
| Fmr LLC | 7.57M | ▼ 95.86K |
| Ubs Group AG | 7.56M | ▲ 406.58K |
| Amundi | 6.51M | ▼ 123.41K |
| Select Equity Group, L.P. | 5.77M | ▲ 90.04K |
Held by 146 ETFs
Biggest fund positions in ALC by dollar value.
Our ALC coverage
Recent articles, reports, and earnings notes.

Alcon AG (ALC): Unity and Dry-Eye Growth Drive the Case
Alcon is pairing strong Unity equipment momentum with faster dry-eye growth, while cash flow and buybacks support the bull case. Valuation is not cheap, but guidance and mix shift keep the stock constructive.

Should You Buy the Tarsier Pharma IPO? Here's the Setup
Tarsier Pharma Ltd. (NYSE: TARX) is expected to list on 2026-07-09, with 5,000,000 shares priced at $8.00 to $10.00 each. The company is a late-stage ophthalmic biotech with no product revenue yet, so the setup hinges on clinical progress rather than current sales.

Alcon (ALC): Quality Medtech Near Fair Value
Alcon is a steady eye-care compounder with recurring revenue, new product momentum, and a disciplined balance sheet. The stock looks constructive, but not deeply cheap, after solid FY2025 growth and a still-elevated valuation.
Want a deeper read on ALC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Alcon: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 11
Alcon Inc. (ALC) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 11
ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock Down
zacks.com · Nov 11
Alcon shares fall as tighter eye-care market outlook raises growth concerns
reuters.com · Nov 11
Alcon (ALC) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com · Nov 10
Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 Growth
businesswire.com · Nov 10
Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 Growth
businesswire.com · Nov 10
Algoma Central Corporation Announces Closing of Over-Allotment Option of Additional Debentures
businesswire.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.